Lumida
/BCPC
⌘K
Balchem Corp

Balchem Corp

BCPC
$163.35USD↓-1.73%-2.88 today

MARKET CAP

5.2B

P/E (TTM)

31.1x

FWD P/E

27.7x

DAY RANGE

$163 – $169

52W RANGE

$139
$184

AI Summary

Stalk
StalkMedium

BCPC remains in a clear uptrend across both long- and medium-term horizons, supported by a Stage 2 advance and a recent Momentum Breakout on expanding volume. Short-term conditions are overextended and overbought, suggesting execution should be deferred. Optimal engagement zones lie near the confluence of the rising 9-, 21-, and 50-day EMAs, where pullbacks should be met with demand. Overall, patience for a corrective reset is warranted despite structural bullishness.

  • ↑Q1 revenue of $271M (+8.1% YoY), net income up 8.7% to $40M, EBITDA margin at 27.4%.
  • ↑Free cash flow of $34M enables disciplined capital allocation via dividends and share repurchases.
  • ↓Raw material inflation in animal nutrition threatens margin sustainability.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Balchem Corporation (NASDAQ: BCPC) operates within the specialty nutrition industry, focusing on three core segments: human nutrition and health, animal nutrition and health, and specialty products. The company is strategically positioned to capture growth from increasing consumer demand for nutrient-dense, healthier food options, and it emphasizes research-driven products and sustainability. Balchem's commitment to innovative delivery systems and ingredient formulations allows it to align with ongoing health trends, making it a significant player within its market.

Bull says

  • ↑Q1 revenue of $271M (+8.1% YoY), net income up 8.7% to $40M, EBITDA margin at 27.4%.
  • ↑Free cash flow of $34M enables disciplined capital allocation via dividends and share repurchases.
  • ↑Human nutrition segment growth driven by health-focused product demand and formulation expertise.
  • ↑Gross margin improved to 37.3% (+210 bps YoY) from manufacturing efficiencies.
  • ↑Strong profitability profile with low leverage and low volatility reduces financial risk.
  • ↑International expansion initiatives target new markets to sustain long-term growth.

Bear says

  • ↓Raw material inflation in animal nutrition threatens margin sustainability.
  • ↓Tariff impacts of ~$25M and geopolitical tensions risk supply-chain disruptions.
  • ↓CFO warns of potential margin erosion despite record EBITDA performance.
  • ↓High short interest and negative earnings yield reflect market doubts.
  • ↓Geopolitical conflicts in the Middle East could disrupt sourcing and logistics.
  • ↓Negative momentum and poor earnings revision trends underscore profitability uncertainty.

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026neutral

Transcript signals

Bull points

  • We are really excited about the results of this most recent study, you know, specifically for servicing postmenopausal women in that community and that targeted market. But it does suggest that older adults can benefit from vitacholine intake more broadly. And that is a huge market compared to the prenatal market that you mentioned.
  • The first quarter was a strong start to 2026. Our record first quarter net sales of $271 million were 8.1% higher than prior year, driven by strength across all three segments, human nutrition and health, animal nutrition and health, and specialty products.
  • Our gross margin dollars were 101 million, up 14.6%, and our gross margin percent expanded to 37.3% of sales, up 210 basis points. The gross margin performance was driven primarily by the sales growth and manufacturing efficiencies, partially offset by raw material inflation.

Bear points

  • But regardless of that, the results are up, sales are up, demand is up, which is what you would expect given the current situation with increased activity in that part of the economy. So we are seeing new business from that. Again, it's not to a material nature. And we strongly believe it will never return to what it once was
  • while we are likely to experience some modest margin compression resulting from the timing lag that occurs between input cost inflation and pricing adjustments,
  • We are once again entering a period of significant inflation, largely petrochemical-based and primarily impacting our animal nutrition and health segment, as well as potential supply chain disruptions due to the ongoing conflict in the Middle East.
Read full transcript analysis ›